Claims for Patent: 10,301,280

Summary for Patent: 10,301,280

Title:	Compounds and methods for kinase modulation, and indications therefor
Abstract:	Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.
Inventor(s):	Wu; Guoxian (Foster City, CA), Chan; Katrina (Fremont, CA), Ewing; Todd (Walnut Creek, CA), Ibrahim; Prabha N. (Mountain View, CA), Lin; Jack (Hercules, CA), Nespi; Marika (Berkeley, CA), Spevak; Wayne (Berkeley, CA), Zhang; Ying (Fremont, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	15/620,396
Patent Claims:	1. A method for treating a subject suffering from a disease or condition selected from Alzheimer's disease (AD), Parkinson's disease, melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, sarcoma, gastrointestinal carcinoma, liver cancer, biliary tract carcinoma, bile duct carcinoma, colorectal cancer, lung cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, renal cancer, ovarian cancer, adrenocortical carcinoma, prostate cancer, lymphoma, neurofibromatosis, gastrointestinal stromal tumors, acute myeloid leukemia, myelodysplastic syndrome, leukemia, tumor angiogenesis, medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, pheochromocytoma, cancer-related pain and mastocytosis, said method comprising administering to the subject in need thereof an effective amount of a compound having Formula (IV): ##STR00429## or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: ring A is a 5-membered fused heteroaryl ring having from 1-3 heteroatoms as ring members selected from O, N, or S; each R.sup.7 is independently selected from C.sub.1-6alkyl, deuterated C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.2-6alkenyl, C.sub.2-6alkynyl, --X.sup.1-aryl, aryl-C.sub.1-4alkylene-X.sup.1--, heteroaryl-C.sub.1-4 alkylene-X.sup.1--, C.sub.3-6cycloalkyl-X.sup.1--, C.sub.3-6cycloalkyl-C.sub.1-4alkylene-X.sup.1--, C.sub.3-6cycloalkenyl-X.sup.1--, CH.sub.2.dbd.CH--X.sup.1, C.sub.3-6cycloalkyl-C.sub.2-4alkenylene-X.sup.1--, C.sub.3-6cycloalkyl-C.sub.2-4alkynylene-X.sup.1--, heterocyclyl-X.sup.1--, heterocyclyl-C.sub.1-4alkylene-X.sup.1-- or R.sup.8, wherein R.sup.8 is selected from halogen, --CN, --OH, --NH.sub.2, --NO.sub.2, --C(O)OH, --C(S)OH, --C(O)NH.sub.2, --C(S)NH.sub.2, --S(O).sub.2NH.sub.2, --NHC(O)NH.sub.2, --NHC(S)NH.sub.2, --NHS(O).sub.2NH.sub.2, --C(NH)NH.sub.2, --OR.sup.a, --SR.sup.a, --OC(O)R.sup.a, --OC(S)R.sup.a, --C(O)R.sup.a, --C(S)R.sup.a, --C(S)OR.sup.a, --S(O)R.sup.a, --S(O).sub.2R.sup.a, --C(O)NHR.sup.a, --C(S)NHR.sup.a, --C(O)NR.sup.aR.sup.a, --C(S)NR.sup.aR.sup.a, --S(O).sub.2NHR.sup.a, --S(O).sub.2NR.sup.aR.sup.a, --C(NH)NHR.sup.a, --C(NH)NR.sup.aR.sup.a, --NHC(O)R.sup.a, --NHC(S)R.sup.a, --NR.sup.aC(O)R.sup.a, --NR.sup.aC(S)R.sup.a, --NHS(O).sub.2R.sup.a, --NR.sup.aS(O).sub.2R.sup.a, --NHC(O)NHR.sup.a, --NHC(S)NHR.sup.a, --NR.sup.aC(O)NH.sub.2, --NR.sup.aC(S)NH.sub.2, --NR.sup.aC(O)NHR.sup.a, --NR.sup.aC(S)NHR.sup.a, --NHC(O)NR.sup.aR.sup.a, --NHC(S)NR.sup.aR.sup.a, --NR.sup.aC(O)NR.sup.aR.sup.a, --NR.sup.aC(S)NR.sup.aR.sup.a, --NHS(O).sub.2NHR.sup.a, --NR.sup.aS(O).sub.2NH.sub.2, --NR.sup.aS(O).sub.2NHR.sup.a, --NHS(O).sub.2NR.sup.aR.sup.a, --NR.sup.aS(O).sub.2NR.sup.aR.sup.a, --NHR.sup.a, or --NR.sup.aR.sup.a, wherein each R.sup.a is independently selected from C.sub.1-6alkyl, aryl, aryl-C.sub.1-2alkyl, C.sub.3-6cycloalkyl, C.sub.3-6cycloalkyl-C.sub.1-4alkyl, heteroaryl, heteroaryl-C.sub.1-4alkyl, heterocycloalkyl, or heterocycloalkyl-C.sub.1-4alkyl, wherein each R.sup.a is further optionally substituted with 1-3 R.sup.b substituents independently selected from C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen, C.sub.1-6 haloalkyl, or C.sub.1-6 haloalkoxy; wherein X.sup.1 is a bond or --C(O)-- and wherein R.sup.7 is optionally substituted with from 1-5 R.sup.9 members selected from halogen, --CH.dbd.CH.sub.2, --CN, --OH, --NH.sub.2, --NO.sub.2, --C(O)OH, --C(S)OH, --C(O)NH.sub.2, --C(S)NH.sub.2, --S(O).sub.2NH.sub.2, --NHC(O)NH.sub.2, --NHC(S)NH.sub.2, --NHS(O).sub.2NH.sub.2, --C(NH)NH.sub.2, --OR.sup.c, --SR.sup.c, --OC(O)R.sup.c, --OC(S)R.sup.c, --P(.dbd.O)HR.sup.c, --P(.dbd.O)R.sup.cR.sup.c, --PH(.dbd.O)OR.sup.c, --P(.dbd.O)(OR.sup.c).sub.2, --OP(.dbd.O)(OR.sup.c).sub.2, --C(O)R.sup.c, --C(S)R.sup.c, --C(O)OR.sup.c, --C(S)OR.sup.c, --S(O)R.sup.c, --S(O).sub.2R.sup.c, --C(O)NHR.sup.c, --C(S)NHR.sup.c, --C(O)NR.sup.cR.sup.c, --C(S)NR.sup.cR.sup.c, --S(O).sub.2NHR.sup.c, --S(O).sub.2NR.sup.cR.sup.c, --C(NH)NHR.sup.c, --C(NH)NR.sup.cR.sup.c, --NHC(O)R.sup.c, --NHC(S)R.sup.c, --NR.sup.cC(O)R.sup.c, --NR.sup.cC(S)R.sup.c, --NHS(O).sub.2R.sup.c, --NR.sup.cS(O).sub.2R.sup.c, --NHC(O)NHR.sup.c, --NHC(S)NHR.sup.c, --NR.sup.cC(O)NH.sub.2, --NR.sup.cC(S)NH.sub.2, --NR.sup.cC(O)NHR.sup.c, --NR.sup.cC(S)NHR.sup.c, --NHC(O)NR.sup.cR.sup.c, --NHC(S)NR.sup.cR.sup.c, --NR.sup.cC(O)NR.sup.cR.sup.c, --NR.sup.cC(S)NR.sup.cR.sup.c, --NHS(O).sub.2NHR.sup.c, --NR.sup.cS(O).sub.2NH.sub.2, --NR.sup.cS(O).sub.2NHR.sup.c, --NHS(O).sub.2NR.sup.cR.sup.c, --NR.sup.cS(O).sub.2NR.sup.cR.sup.c, --NHR.sup.c, R.sup.c, or --NR.sup.cR.sup.c; or two adjacent R.sup.9 substituents, together with the atoms to which they are attached, form a 5 or 6-membered ring having from 0-2 heteroatoms selected from O, N, or S; wherein each R.sup.c is independently selected from C.sub.1-6alkyl, aryl, aryl-C.sub.2alkyl, C.sub.3-6cycloalkyl, C.sub.3-6cycloalkyl-C.sub.1-4alkyl, heteroaryl, heteroaryl-C.sub.1-4alkyl, heterocycloalkyl, or heterocycloalkyl-C.sub.1-4alkyl, wherein each R.sup.c is further optionally substituted with from 1-3 R.sup.d groups independently selected from --CN, --OH, --N(R.sup.e)(R.sup.e), --NO.sub.2, --C(O)OH, --C(O)NH.sub.2, --S(O).sub.2NH.sub.2, --NHC(O)NH.sub.2, --C(NH)NH.sub.2, --OC(O)R.sup.e, --OC(S)R.sup.e, --C(O)R.sup.e, --C(S)R.sup.e, --C(O)OR.sup.e, --P(.dbd.O)HR.sup.e, --P(.dbd.O)R.sup.eR.sup.e, --PH(.dbd.O)OR.sup.e, --P(.dbd.O)(OR.sup.e).sub.2, --OP(.dbd.O)(OR.sup.e).sub.2, --S(O).sub.2R.sup.e, --C(O)NHR.sup.e, C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen, C.sub.1-6 haloalkyl, or C.sub.1-6 haloalkoxy, wherein each R.sup.e is independently C.sub.1-6alkyl; or two adjacent R.sup.7 substituents together with the atoms to which they are attached form a 4-, 5-, or 6-membered carbocyclic ring or heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N, or S; Y.sup.2 is C--R.sup.10, wherein R.sup.10 is H, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.2-6alkenyl, C.sub.2-6alkynyl, aryl-C.sub.1-4alkyl-, heteroaryl-C.sub.1-4 alkyl-, C.sub.3-6cycloalkyl-C.sub.1-4alkyl-, C.sub.3-6cycloalkenyl-C.sub.1-4alkyl-, CH.sub.2.dbd.CH--X.sup.2--, C.sub.3-6cycloalkyl-C.sub.2-4alkenylene-X.sup.2--, C.sub.3-6cycloalkyl-C.sub.2-4alkynylene-X.sup.2--, heterocyclyl-C.sub.1-4alkyl-, or R.sup.8, each of which is optionally substituted with from 1-5 R.sup.9 groups; wherein X.sup.2 is C.sub.1-4alkylene, --O--, --S--, or --NH--; R.sup.3 and R.sup.4 are each independently selected from H, halogen, C.sub.1-6 alkyl, C.sub.1-4haloalkyl, C.sub.1-4haloalkoxy, cyclopropyl, phenyl, --CN, CN--CH.sub.2--, C.sub.1-6alkoxy, or R.sup.g; or R.sup.3 and R.sup.4 are taken together with the atoms to which they are attached form an optionally substituted 4 to 8-membered ring having from 0-2 heteroatoms as ring members selected from O, N, or S; wherein R.sup.g is --OH, --NH.sub.2, --NO.sub.2, --C(O)OH, --C(S)OH, --C(O)NH.sub.2, --C(S)NH.sub.2, --S(O).sub.2NH.sub.2, --NHC(O)NH.sub.2, --NHC(S)NH.sub.2, --NHS(O).sub.2NH.sub.2, --C(NH)NH.sub.2, --OR.sup.h, --SR.sup.h, --OC(O)R.sup.h, --OC(S)R.sup.h, --C(O)R.sup.h, --C(S)R.sup.h, --C(O)OR.sup.h, --C(S)OR.sup.h, --S(O)R.sup.h, --S(O).sub.2R.sup.h, --C(O)NHR.sup.h, --C(S)NHR.sup.h, --C(O)NR.sup.hR.sup.h, --C(S)NR.sup.hR.sup.h, --S(O).sub.2NHR.sup.h, --S(O).sub.2NR.sup.hR.sup.h, --C(NH)NHR.sup.h, --C(NH)NR.sup.hR.sup.h, --NHC(O)R.sup.h, --NHC(S)R.sup.h, --NR.sup.hC(O)R.sup.h, --NR.sup.hC(S)R.sup.h, --NHS(O).sub.2R.sup.h, --NR.sup.hS(O).sub.2R.sup.h, --NHC(O)NHR.sup.h, --NHC(S)NHR.sup.h, --NR.sup.hC(O)NH.sub.2, --NR.sup.hC(S)NH.sub.2, --NR.sup.hC(O)NHR.sup.h, --NR.sup.hC(S)NHR.sup.h, --NHC(O)NR.sup.hR.sup.h, --NHC(S)NR.sup.hR.sup.h, --NR.sup.hC(O)NR.sup.hR.sup.h, --NR.sup.hC(S)NR.sup.hR.sup.h, --NHS(O).sub.2NHR.sup.h, --NR.sup.hS(O).sub.2NH.sub.2, --NR.sup.hS(O).sub.2NHR.sup.h, --NHS(O).sub.2NR.sup.hR.sup.h, --NR.sup.hS(O).sub.2NR.sup.hR.sup.h, --NHR.sup.h, or --NR.sup.hR.sup.h, wherein each R.sup.h is independently H or Ca-2alkyl; R.sup.5 is H or C.sub.1-4alkyl; Y.sup.1 is N or C; Y.sup.3 is CH; and the subscript m is 0, 1, or 2. 2. The method according to claim 1, wherein the compound is of Formula (IVa), (IVb), (IVc), or (IVd): ##STR00430## 3. The method according to claim 1, wherein the compound is of Formula (IVa-2): ##STR00431## 4. The method according to claim 3, wherein R.sup.10 is H. 5. The method according to claim 3, wherein R.sup.3 and R.sup.4 are each independently H, halogen, C.sub.1-6alkyl, C.sub.1-6alkoxy, cyclopropyl, --CN, C.sub.1-4haloalkyl, or C.sub.1-4haloalkoxy; or R.sup.3 and R.sup.4 are taken together with the atoms to which they are attached form an optionally substituted fused 4 to 8-membered ring having from 0-2 heteroatoms selected from N or S. 6. The method according to claim 3, wherein R.sup.3 and R.sup.4 are each independently selected from H, Br, Cl, methyl, ethyl, cyclopropyl, --CN, CF.sub.3, CHF.sub.2, CH.sub.2F, --OCH.sub.3, --OCF.sub.3, --OCHF.sub.2 or --OCH.sub.2F, CNCH.sub.2--, NH.sub.2C(O)--, CH.sub.3NHCO--, or CH.sub.3C(O)NH--; or R.sup.3 and R.sup.4 are taken together with the atoms to which they are attached form a fused ring selected from benzene, pyridine, pyrimidine, pyrazine, pyridazine, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cyclooctane, or cyclooctatriene, each of which is optionally substituted. 7. The method according to claim 3, wherein R.sup.7 is selected from halogen, --CN, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.2-6alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-4alkyl, aryl, aryl-C.sub.1-4alkyl, heteroaryl, heteroaryl-C.sub.1-4 alkyl, heterocyclyl or heterocyclyl-C.sub.1-4alkyl, --C(O)--R.sup.a, --C(O)NHR.sup.a, --C(O)NR.sup.aR.sup.a, --NHC(O)R.sup.a, --NHC(O)NHR.sup.a, --NHC(O)NR.sup.aR.sup.a, --NR.sup.aR.sup.a, --NHR.sup.a, --OC(O)R.sup.a, --SO.sub.2R.sup.a, --NHSO.sub.2R.sup.a, --NHSO.sub.2NHR.sup.a, --NHSO.sub.2NR.sup.aR.sup.a, --SO.sub.2NHR.sup.a, or --SO.sub.2NR.sup.aR.sup.a, wherein at each occurrence R.sup.7 is optionally substituted with from 1-4 R.sup.9 members, wherein each R.sup.9 is independently selected from halogen, --CN, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6 haloalkyl, C.sub.1-6 haloalkoxy, C.sub.3-6cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-4alkyl, aryl, aryl-C.sub.1-2alkyl, heteroaryl, heteroaryl-C.sub.1-4 alkyl, heterocyclyl, or heterocyclyl-C.sub.1-4alkyl or the two adjacent R.sup.9 substituents on an aromatic ring are taken together to form a 5 or 6-membered ring having from 0-2 heteroatoms selected from O, N, or S. 8. The method according to claim 3, wherein R.sup.7 is vinyl, ethynyl, deuterated C.sub.1-6alkyl, C.sub.1-6alkyl, halogen, C.sub.1-6alkoxy, 2-cyclopropylethynyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, benzyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiozolyl, 4-thiozolyl, 5-thiozolyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, cyclopropyl, cyclopropylmethyl, cyclopropylcarbonyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, benzoyl, phenylcarbamoyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-piperazinyl, 2-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-cyclopentenyl, 1-cyclohexenyl, 1,2,3,6-tetrahydropyridin-4-yl, 1,2,3,6-tetrahydropyridin-5-yl, 2,5-dihydro-1H-pyrrol-3-yl, 2,5-dihydro-pyrrol-1-yl, 2,3-dihydro-1,4-benzodioxin-5-yl, 1,3-benzodioxol-4-yl, 1,3-benzodioxol-5-yl, indan-1-yl, indan-2-yl, 1,2-benzoxazolyl, or 1,3-benzoxazolyl, each of which is optionally substituted with from 1-4 R.sup.9 members. 9. The method according to claim 3, wherein R.sup.7 is selected from Cl, Br, phenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 1-cyclopropylcarbonyl-1,2,3,6-tetrahydropyridin-4-yl, 1-morpholinocarbonyl, 1,2,3,6-tetrahydropyridin-4-yl, 1,2,3,6-tetrahydropyridin-5-yl, 1,3-dimethyl-pyrazol-4-yl, 1-(4-piperidinyl)pyrazol-4-yl, 3,4-dimethyl-1H-pyrazol-5-yl, 1-(cyclopropylcarbonyl)-2,5-dihydro-pyrrol-3-yl, 3-fluoro-propynyl, or 3,5-dimethyl-isoxazol-4-yl, 5-thiazolyl, each of which is optionally substituted with from 1-3 substituents independently selected from F, Cl, --CH.sub.3, ethyl, propyl, isopropyl, 2-methylpropyl, CD.sub.3, --OCH.sub.3, CN, CH.sub.2F, --CF.sub.2H, CF.sub.3, CF.sub.3O--, CHF.sub.2O--, CH.sub.2FO--, NH.sub.2, --N(CH.sub.3).sub.2, --NHCH.sub.3, CH.sub.3CONH--, NH.sub.2C(O)--, CH.sub.3NHC(O)--, (CH.sub.3).sub.2NC(O)--, cyclopropyl, 1-cyanocyclopropyl, 4-morpholinyl, 4-morpholinylmethyl, 4-thiomorpholinyl, 4-morpholinylcarbonyl, 4-thiomorpholinylcarbonyl, 4-morpholinylmethylcarbonyl, 4-thiomorpholinylmethylcarbonyl, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, --PH(.dbd.O)(C.sub.1-4alkyl), --P(.dbd.O)(C.sub.1-4alkyl).sub.2, --PH(.dbd.O)(OC.sub.1-4alkyl), --P(.dbd.O)(OC.sub.1-4alkyl).sub.2, --OP(.dbd.O)(OC.sub.1-4alkyl).sub.2, 4-piperidinyl, 4-piperidinylcarbonyl, 1-piperidinylcarbonyl, 1-piperazinylcarbonyl, t-butoxycarbonyl, 2-(4-morpholinyl)-ethyl, 2-(4-morpholinyl)-ethoxy, 1,2-dihydroxyethylcarbonyl, 3-methoxypropoxy, 1-pyrrolidinyl, phenyl-SO.sub.2NH--, C.sub.1-4alkyl-SO.sub.2NH--, cyclopropyl-SO.sub.2NH--, p-CH.sub.3C6H.sub.4SO.sub.2NH--, NH.sub.2SO.sub.2--, C.sub.1-4alkyl-NHSO.sub.2--, (C.sub.1-4alkyl).sub.2NSO.sub.2--, C.sub.1-4alkyl-NHC(O)--, C.sub.1-4alkyl-C(O)--, C.sub.1-4alkyl-SO.sub.2--, 4-morpholinyl-C.sub.1-4alkoxy, or 1-pyrrolidinylcarbonyl. 10. The method according to claim 3, wherein R.sup.5 is H. 11. A method for treating a subject suffering from disease or condition selected from Alzheimer's disease (AD), Parkinson's disease, melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, sarcoma, gastrointestinal carcinoma, liver cancer, biliary tract carcinoma, bile duct carcinoma, colorectal cancer, lung cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, renal cancer, ovarian cancer, adrenocortical carcinoma, prostate cancer, lymphoma, neurofibromatosis, gastrointestinal stromal tumors, acute myeloid leukemia, myelodysplastic syndrome, leukemia, tumor angiogenesis, medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, pheochromocytoma, cancer-related pain and mastocytosis, said method comprising administering to the subject in need thereof an effective amount of a compound of structure: ##STR00432## ##STR00433## ##STR00434## ##STR00435## ##STR00436## ##STR00437## ##STR00438## ##STR00439## ##STR00440## ##STR00441## ##STR00442## ##STR00443## ##STR00444## ##STR00445## ##STR00446## ##STR00447## ##STR00448## ##STR00449## ##STR00450## ##STR00451## ##STR00452## ##STR00453## ##STR00454## ##STR00455## ##STR00456## ##STR00457## ##STR00458## ##STR00459## ##STR00460## ##STR00461## ##STR00462## ##STR00463## ##STR00464## ##STR00465## ##STR00466## ##STR00467## ##STR00468## or a pharmaceutically acceptable salt thereof. 12. The method according to claim 3, wherein the compound has the following structure: ##STR00469## or a pharmaceutically acceptable salt-thereof. 13. The method according to claim 3, wherein the compound has the following structure: ##STR00470## or a pharmaceutically acceptable salt thereof. 14. The method according to claim 3, wherein the compound has the following structure ##STR00471## or a pharmaceutically acceptable salt thereof. 15. The method according to claim 3, wherein the compound has the following structure: ##STR00472## or a pharmaceutically acceptable salt thereof. 16. The method according to claim 3, wherein the compound has the following structure: ##STR00473## or a pharmaceutically acceptable salt thereof. 17. The method according to claim 3, wherein the compound has the following structure: ##STR00474## or a pharmaceutically acceptable salt thereof. 18. The method according to claim 11, wherein the disease or condition is melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract carcinoma or cancer-related pain. 19. The method according to any one of claims 12-17, wherein the disease or condition is acute myeloid leukemia, gastrointestinal stromal tumors, or mastocytosis. 20. The method according to claim 1, further comprising administering to the subject a therapeutic agent in combination with the compound having Formula IV, where the therapeutic agent is adozelesin, altretamine, bendamustine, bizelesin, busulfan, carboplatin, carboquone, carmofur, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, etoglucid, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mannosulfan, mechlorethamine, melphalan, mitobronitol, nedaplatin, nimustine, oxaliplatin, piposulfan, prednimustine, procarbazine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, thiotepa, treosulfan, triaziquone, triethylenemelamine, triplatin tetranitrate, trofosphamide, uramustine, clarubicin, amrubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, idarubicin, menogaril, mitomycin, neocarzinostatin, pentostatin, pirarubicin, plicamycin, valrubicin, zorubicin, aminopterin, azacitidine, azathioprine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, tegafur-uracil, thioguanine, trimethoprim, trimetrexate, vidarabine, alemtuzumab, bevacizumab, cetuximab, galiximab, gemtuzumab, panitumumab, pertuzumab, rituximab, brentuximab, tositumomab, trastuzumab, 90 Y ibritumomab tiuxetan, ipilimumab, tremelimumab, anti-CTLA-4 antibodies, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, toremifene, DJ-927, docetaxel, TPI 287, larotaxel, ortataxel, paclitaxel, DHA-paclitaxel, tesetaxel, alitretinoin, bexarotene, fenretinide, isotretinoin, tretinoin, demecolcine, homoharringtonine, vinblastine, vincristine, vindesine, vinflunine, vinorelbine; GW786034, neovastat, ABT-510, 2-methoxyestradiol, lenalidomide, thalidomide; a topoisomerase inhibitor, amsacrine, belotecan, edotecarin, etoposide, etoposide phosphate, exatecan, irinotecan, lucanthone, mitoxantrone, pixantrone, rubitecan, teniposide, topotecan, 9-aminocamptothecin; axitinib, dasatinib, erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, motesanib diphosphate, nilotinib, seliciclib, sorafenib, sunitinib malate, AEE-788, BMS-599626, 7-hydroxystaurosporine, vemurafenib, dabrafenib, PLX3397, selumetinib, and vatalanib, bortezomib, geldanamycin, rapamycin, imiquimod, interferon, interleukin-2; 3-amino-2-carboxyaldehyde thiosemicarbazone, altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, mTOR inhibitors, PI3K inhibitors, Cdk4 inhibitors, Akt inhibitors, Hsp90 inhibitors, farnesyltransferase inhibitors, or Aromatase inhibitors. 21. The method according to claim 11, further comprising administering to the subject a therapeutic agent in combination with the compound, where the therapeutic agent is adozelesin, altretamine, bendamustine, bizelesin, busulfan, carboplatin, carboquone, carmofur, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, etoglucid, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mannosulfan, mechlorethamine, melphalan, mitobronitol, nedaplatin, nimustine, oxaliplatin, piposulfan, prednimustine, procarbazine, ranimustine, satraplatin, semustine, streptozocin, temozolomide, thiotepa, treosulfan, triaziquone, triethylenemelamine, triplatin tetranitrate, trofosphamide, uramustine, clarubicin, amrubicin, bleomycin, dactinomycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, idarubicin, menogaril, mitomycin, neocarzinostatin, pentostatin, pirarubicin, plicamycin, valrubicin, zorubicin, aminopterin, azacitidine, azathioprine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, tegafur-uracil, thioguanine, trimethoprim, trimetrexate, vidarabine, alemtuzumab, bevacizumab, cetuximab, galiximab, gemtuzumab, panitumumab, pertuzumab, rituximab, brentuximab, tositumomab, trastuzumab, 90 Y ibritumomab tiuxetan, ipilimumab, tremelimumab, anti-CTLA-4 antibodies, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, toremifene, DJ-927, docetaxel, TPI 287, larotaxel, ortataxel, paclitaxel, DHA-paclitaxel, tesetaxel, alitretinoin, bexarotene, fenretinide, isotretinoin, tretinoin, demecolcine, homoharringtonine, vinblastine, vincristine, vindesine, vinflunine, vinorelbine; GW786034, neovastat, ABT-510, 2-methoxyestradiol, lenalidomide, thalidomide; a topoisomerase inhibitor, amsacrine, belotecan, edotecarin, etoposide, etoposide phosphate, exatecan, irinotecan, lucanthone, mitoxantrone, pixantrone, rubitecan, teniposide, topotecan, 9-aminocamptothecin; axitinib, dasatinib, erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, motesanib diphosphate, nilotinib, seliciclib, sorafenib, sunitinib malate, AEE-788, BMS-599626, 7-hydroxystaurosporine, vemurafenib, dabrafenib, PLX3397, selumetinib, and vatalanib, bortezomib, geldanamycin, rapamycin, imiquimod, interferon, interleukin-2; 3-amino-2-carboxyaldehyde thiosemicarbazone, altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, mTOR inhibitors, PI3K inhibitors, Cdk4 inhibitors, Akt inhibitors, Hsp90 inhibitors, farnesyltransferase inhibitors, or Aromatase inhibitors.

Details for Patent 10,301,280

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2032-12-21
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2032-12-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-12-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-12-21
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2032-12-21
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2032-12-21